The Veracyte Diagnostics Platform

Unlocking a deeper understanding of cancer and fueling evidence generation.

What is the Veracyte Diagnostics Platform?

The Veracyte Diagnostics Platform is a unique approach to creating cancer molecular tests that grows stronger with each sample.

By performing whole-ome profiling on every test, we create an ever-expanding database that powers new insights, generates robust clinical evidence, and enables new applications across the cancer care continuum. 

Veracyte Diagnostics Platform

More data

Transcriptomes, genomes, complementary data sources, and clinical outcomes

More insights

From AI-assisted data mining, multimodal analysis, and bioinformatics analysis

More evidence

From the analysis of real-world data and clinical studies

More utility

For current tests and new cancer applications

How Our Platform Works

Four integrated capabilities fuel innovation

Our integrated approach delivers high-value cancer insights with four core capabilities. Each builds on the others to fuel comprehensive analysis that transforms patient care.

Comprehensive genomic profiling of every patient sample

  • We perform whole-ome profiling on each sample, providing not just a single test result, but also creating a deep resource for future innovation.
  • We combine multiple data sources, including genomic data, digital pathology scans and clinical outcomes to expand the potential for insights. Using this approach, we have built the largest whole-transcriptome databases for prostate cancer and thyroid nodules in the world.

AI-powered analysis unlocks deeper biological understanding

  • We apply advanced AI and bioinformatics to analyze these comprehensive datasets, allowing us to explore the answers to novel clinical questions.
  • Our platform creates a flywheel for new insights that has generated over >600 peer-reviewed publications.
  • >35 Phase 2 and 3 clinical trials evaluating our tests’ performance and clinical utility.

Rigorous clinical studies help drive provider confidence

  • We partner with leading researchers and organizations to support studies across diverse patient populations.
  • The evidence that results supports widespread clinical adoption and reimbursement.
  • Our tests are widely recommended in clinical guidelines and Decipher Prostate is the only gene expression test with high evidence quality status in the most recent NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for prostate cancer.1

Expanding test applications address unmet clinical needs

  • With our approach, we accelerate the translation of discoveries into actionable clinical insights that further personalize cancer care.
  • Our platform has enabled us to rapidly grow the utility of our tests to answer more clinical questions (e.g. Decipher Prostate for treatment selection and Afirma for suspected or confirmed cancerous nodules vs. indeterminate nodules).
  • Our platform has allowed us to expand the use of our tests across the patient journey (e.g., Decipher for metastatic patients and Afirma for Bethesda V/VI patients).

The Veracyte Diagnostics Platform: proven results helping to transform cancer care2

>800K

Patients benefited from our genomic tests across multiple cancer types

Explore Technology

>200K whole slide images

Advanced AI models from tumor samples with outcomes data, complementing molecular insights with digital pathology

 

>35

Phase 2 & 3 trials evaluating our tests

Explore Clinical Studies

>600

Scientific publications and references validating our platform’s clinical utility

View Publications

>1.2B

Gene expression measurements powering continuous discovery

Decipher GRID Afirma GRID

Market-leading cancer tests

Most widely used genomic tests in prostate and thyroid cancers

Decipher Prostate Afirma Thyroid

Leading experts validate our whole-ome approach

By analyzing whole-transcriptome data, we showed that Decipher Prostate can identify which patients with metastatic prostate cancer are likely to benefit from docetaxel—and which are not. This gives providers a potentially powerful new tool to personalize treatment and reduce unnecessary toxicity for this growing patient population.”2

Gerhardt Attard, M.D., Ph.D. University College London Cancer Institute and STAMPEDE trial co-investigator

Did you know?

The STAMPEDE trial represents one of the largest, most innovative prostate cancer trials ever conducted, involving over 12,000 patients across multiple countries.

GRID research platform: accelerating cancer discovery through collaboration

Enabling breakthrough discoveries through our expansive curated genomic databases in cancer research.

The Genomic Resource for Intelligent Discovery (GRID) platform provides researchers with comprehensive whole-transcriptome databases and clinical data to accelerate cancer discoveries. Currently available for urologic and thyroid cancers, the GRID platform enables collaborative research that advances our collective understanding of cancer biology and treatment optimization.

Explore Decipher GRID Explore Afirma GRID

Advancing cancer care through next-generation diagnostics innovation

A health care provider in a white coat and stethoscope attentively talks to a patient. The setting is a bright medical office, conveying professionalism and care.

By harnessing whole-ome insights, circulating tumor DNA (ctDNA), digital pathology, and AI, we enable a more complete and dynamic view of each patient’s tumor to inform precise, personalized treatment at every step.

A health care provider in a white coat talks to an older man sitting on an exam table in a medical office. The patient looks attentive and slightly concerned.

By interrogating our ever-expanding databases of whole-transcriptome and genome profiles, we identify new opportunities—such as in metastatic prostate cancer—to help providers guide care based on a detailed understanding of each patient’s tumor biology.

A lab worker in a white lab coat examines a sample through a microscope, focused and determined. The lab setting is bright and clinical.

We leverage AI analysis and long-term outcome data with whole slide images and our extensive whole-transcriptome profiles in prostate cancer to derive new insights.

Our TrueMRD platform uses whole-genome sequencing and AI to create a personalized “fingerprint” for each patient’s tumor to profile the cancer’s genomic signature, and track its recurrence and evolution, over time.

Frequently Asked Questions

View All FAQs

Keep exploring

Clinical Studies

Studies demonstrating the impact of our tests across cancer types.

Discover

Technology & Pipeline

Explore our portfolio of molecular tests, developments, and progress.

Discover

Resource Center

View scientific publications, videos, FAQS, and more.

Explore

Press Releases

New data, partner announcements, and financial reports.

Learn More

Connect with us

Contact Us

References

  1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.5.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed March 18, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org.
    NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  2. Veracyte, Inc. Company data on file. Updated March 2026.

Disclaimers

Decipher testing is available in the United States as part of Veracyte’s CLIA-validated laboratory developed test (LDT) service, and FDA clearance is not required.

This webpage contains forward-looking statements. These forward-looking statements involve risks and uncertainties. For more information, click here.